Table 2.
Characteristics Evaluated for Association with Progression-Free Survival Outcomes
| No. of Patients** |
No. of Events |
Hazard Ratio (90% CI) |
1-Yr PFS Rate (90% CI) |
Log-Rank P Value |
|
|---|---|---|---|---|---|
| Treatment | |||||
| No LCT | 24 | 17 | Ref. | 0.20 (0.07, 0.38) | 0.005 |
| LCT | 25 | 14 | 0.35 (0.18, 0.66) | 0.48 (0.29, 0.66) | |
| Sex | |||||
| Male | 22 | 15 | Ref | 0.27 (0.11, 0.46) | 0.52 |
| Female | 27 | 16 | 0.79 (0.43, 1.45) | 0.41 (0.24, 0.58) | |
| Timing of Metastases |
|||||
| Metachronous | 3 | 2 | Ref | NE [NAR] | N/Ab |
| Synchronous | 46 | 29 | 0.83 (0.24, 2.78) | 0.36 (0.24, 0.50) | |
| Pattern of Failure | |||||
| None | 19 | 1 | Ref | 1.00 (NE [EF]) | N/Ab |
| Locoregional | 5 | 5 | 22.69 (3.73, 137.98) | 0.20 (0.02, 0.52) | |
| Distant | 16 | 16 | 19.13 (3.49, 104.83) | 0.19 (0.06, 0.37) | |
| Both | 9 | 9 | 49.57 (8.47, 290.04) | NE [NAR] | |
| Site of Progression | |||||
| None | 19 | 1 | Ref | 1.00 (NE) | N/Ab |
| Known Lesion | 7 | 7 | 40.10 ( 6.85, 234.78) | 0.14 (0.01, 0.41) | |
| New Lesion | 14 | 14 | 14.51 ( 2.62, 80.21) | 0.21 (0.07, 0.41) | |
| Both | 9 | 9 | 98.50 (16.02, 605.48) | NE [NAR] | |
| Non-Regional Metastases after Front Line Systemic Therapy |
|||||
| 0–1a | 32 | 19 | Ref | 0.38 (0.21, 0.54) | 0.24 |
| 2–3 | 17 | 12 | 1.54 (0.83, 2.85) | 0.28 (0.12, 0.48) | |
| Response to Front Line Systemic Therapy |
|||||
| PR/CR | 18 | 13 | Ref | 0.23 (0.08, 0.42) | 0.48 |
| SD | 31 | 18 | 0.77 (0.41, 1.42) | 0.42 (0.25, 0.58) | |
| CNS Metastases | |||||
| No | 36 | 24 | Ref | 0.28 (0.15, 0.43) | 0.60 |
| Yes | 13 | 7 | 0.80 (0.39, 1.64) | 0.54 (0.26, 0.75) | |
| Nodal Status | |||||
| N0–1 | 23 | 13 | Ref | 0.41 (0.20, 0.60) | 0.49 |
| N2–3 | 26 | 18 | 1.29 (0.70, 2.37) | 0.30 (0.15, 0.46) | |
| Mutation Type | |||||
| None | 41 | 29 | Ref | 0.24 (0.12, 0.38) | 0.012 |
| EGFR/ EML4ALK | 8 | 2 | 0.19 (0.06, 0.64) | 0.88 (0.50, 0.98) |
One patient in the LCT arm contributed zero follow-up time and was eliminated prior to estimating the HR
Patients categorized as having 0 metastatic lesions had had complete resolution or prior treatment to metastatic sites and thus were randomized to receive LCT to the primary tumor vs. maintenance therapy.
P values are not provided when there is insufficient data to make statistical comparisons
Abbreviations: CI, confidence interval; PFS, progression-free survival; LCT, local consolidative therapy; NE [NAR], not evaluable because no at-risk patients remained at 1 year; NE [EF], not evaluable because all patients were event-free at 1 year; PR, partial response; CR, complete response; SD, stable disease; CNS, central nervous system